Lisinopril and Cough: Is Your Blood Pressure Medication Making You Cough?

Why Does Lisinopril Cause a Cough?

Lisinopril belongs to a class of medications called ACE inhibitors (angiotensin-converting enzyme inhibitors), among the most widely prescribed drugs for high blood pressure, heart failure, and kidney protection in people with diabetes.

The cough is a class effect — it is not specific to lisinopril, but is caused by the shared mechanism of every drug in the ACE inhibitor class 1Ref 1Dicpinigaitis PV (2006).Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.5–35% incidence of ACE inhibitor cough; bradykinin/substance P mechanism; resolution 1–4 weeks after stopping; ARB switching recommendation. ACE inhibitors work by blocking an enzyme that converts angiotensin I to angiotensin II. That same enzyme (also known as kininase II) is responsible for breaking down a substance in the airways called bradykinin. When ACE is inhibited, bradykinin accumulates in the respiratory tract. Excess bradykinin and substance P are irritating to airway sensory nerves, triggering the cough reflex 1Ref 1Dicpinigaitis PV (2006).Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.5–35% incidence of ACE inhibitor cough; bradykinin/substance P mechanism; resolution 1–4 weeks after stopping; ARB switching recommendation2Ref 2Yılmaz İ (2019).Angiotensin-Converting Enzyme Inhibitors Induce Cough.Incidence range 3.9–35%; approximately one-fifth of patients discontinue due to cough; higher rates in heart failure vs. hypertension; cough characteristics and mechanism.

Because this is a class mechanism, switching to a different ACE inhibitor — from lisinopril to enalapril or ramipril, for example — will not solve the problem. The same pathway is affected by all drugs in the class.

How Common Is the Lisinopril Cough?

The reported incidence varies considerably across populations and study designs: clinical trials have found rates from 5% to 35% among ACE inhibitor users 1Ref 1Dicpinigaitis PV (2006).Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.5–35% incidence of ACE inhibitor cough; bradykinin/substance P mechanism; resolution 1–4 weeks after stopping; ARB switching recommendation2Ref 2Yılmaz İ (2019).Angiotensin-Converting Enzyme Inhibitors Induce Cough.Incidence range 3.9–35%; approximately one-fifth of patients discontinue due to cough; higher rates in heart failure vs. hypertension; cough characteristics and mechanism. Real-world prescription data tend toward the lower end; formal cough-clinic studies focused on chronic cough patients may show higher rates.

A meaningful proportion of people who develop the cough stop their medication because of it — one review found roughly one in five patients discontinues ACE inhibitor therapy primarily due to cough 2Ref 2Yılmaz İ (2019).Angiotensin-Converting Enzyme Inhibitors Induce Cough.Incidence range 3.9–35%; approximately one-fifth of patients discontinue due to cough; higher rates in heart failure vs. hypertension; cough characteristics and mechanism.

Who is more likely to develop it? - East Asian descent — ACE inhibitor cough is substantially more common in people of East Asian ancestry (approximately 20–45%) compared with European ancestry populations (approximately 10–15%), a difference documented in pharmacogenomic studies and linked in part to variation in the ACE insertion/deletion (I/D) polymorphism 3Ref 3Mu G, Xiang Q, Zhou S, Xie Q, Liu Z, Zhang Z, Cui Y (2019).Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis.ACE I/D polymorphism as predictor of cough risk, especially in East Asian populations; higher incidence in East Asian compared to European ancestry patients - Women appear to experience ACE inhibitor cough more frequently than men, though it affects both sexes - Non-smokers show higher rates than smokers, possibly because smokers have competing causes for chronic cough that change the denominator - People with heart failure (approximately 26%) show higher rates than those treated for hypertension alone (approximately 14%), though distinguishing drug cough from breathlessness-related cough in heart failure is clinically challenging 2Ref 2Yılmaz İ (2019).Angiotensin-Converting Enzyme Inhibitors Induce Cough.Incidence range 3.9–35%; approximately one-fifth of patients discontinue due to cough; higher rates in heart failure vs. hypertension; cough characteristics and mechanism

What Does the Cough Feel and Sound Like?

The ACE inhibitor cough has a recognizable character:

• Dry and non-productive — no mucus or phlegm
• Tickling or scratchy — often described as a persistent tickle at the back of the throat that triggers fits
• Persistent — it does not improve on its own while you remain on the drug; some people have it constantly, others in bouts
• Variable onset — symptoms can begin within hours of the first dose or emerge weeks to months after starting therapy 1Ref 1Dicpinigaitis PV (2006).Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.5–35% incidence of ACE inhibitor cough; bradykinin/substance P mechanism; resolution 1–4 weeks after stopping; ARB switching recommendation. Someone who has been on lisinopril for six months can still develop the cough, which is partly why people often fail to connect it to their medication

Because the onset can be delayed, the medication-cough connection is frequently missed — both by patients and by clinicians who were not expecting it at that point in the course of treatment.

How Do Clinicians Confirm It Is the Medication?

The diagnostic standard is straightforward: stopping the ACE inhibitor under a clinician's supervision and observing whether the cough resolves. Resolution typically takes one to four weeks after the drug is stopped, though cough may occasionally persist for up to three months before fully clearing 1Ref 1Dicpinigaitis PV (2006).Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.5–35% incidence of ACE inhibitor cough; bradykinin/substance P mechanism; resolution 1–4 weeks after stopping; ARB switching recommendation.

Other common causes of a chronic dry cough include: - Acid reflux (GERD) — often worse at night or after meals; may include heartburn or a sensation of postnasal drip - Postnasal drip from allergies or sinusitis — usually accompanied by nasal symptoms - Cough-variant asthma — consider if there is any wheeze, shortness of breath, or cough triggered by cold air or exercise - ACE inhibitor angioedema — a distinct and more serious reaction (see safety section below)

A clinician will sometimes order a chest X-ray to exclude other causes (infection, fluid, lung pathology) or spirometry if asthma or airflow obstruction is a concern. If acid reflux is suspected alongside the medication cough, a trial of acid suppression may be used diagnostically.

What Are the Options If the Medication Is the Cause?

You do not have to choose between blood pressure control and relief from the cough. The most effective solution for most people is switching to a different drug class.

Angiotensin receptor blockers (ARBs) — such as losartan, valsartan, or irbesartan — act on the same part of the renin-angiotensin pathway as ACE inhibitors and provide very similar clinical benefits for blood pressure, heart failure, and diabetic kidney protection. Crucially, ARBs do not block the enzyme that breaks down bradykinin, so they do not cause the cough 1Ref 1Dicpinigaitis PV (2006).Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.5–35% incidence of ACE inhibitor cough; bradykinin/substance P mechanism; resolution 1–4 weeks after stopping; ARB switching recommendation4Ref 4Whelton PK, Carey RM, Aronow WS, et al. (2018).2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.ACE inhibitors and ARBs as first-line agents for hypertension; preferred agents in diabetic kidney disease and heart failure; ARBs as equivalent clinical alternative. The American College of Cardiology / American Heart Association hypertension guidelines recognize both ACE inhibitors and ARBs as first-line agents for hypertension and as preferred treatments in people with diabetes or kidney disease 4Ref 4Whelton PK, Carey RM, Aronow WS, et al. (2018).2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.ACE inhibitors and ARBs as first-line agents for hypertension; preferred agents in diabetic kidney disease and heart failure; ARBs as equivalent clinical alternative.

For the large majority of people who switch from an ACE inhibitor to an ARB, the cough resolves completely within a few weeks. The right ARB choice depends on your specific conditions — heart failure and diabetic nephropathy have specific evidence bases for particular agents — and should be determined by the prescribing clinician.

Do not stop lisinopril on your own. The switch needs to be planned to ensure your blood pressure and any other conditions the drug was treating remain managed throughout the transition.

What About the Rare Complication — Angioedema?

A small number of people on ACE inhibitors develop angioedema — swelling of the lips, tongue, throat, or face. This is caused by the same bradykinin accumulation mechanism, but producing tissue swelling rather than just airway irritation. Angioedema is rare — estimates put its incidence at approximately 0.1–0.7% of people on ACE inhibitors — but because ACE inhibitors are prescribed to tens of millions of people, it accounts for roughly one-third of all emergency department visits for angioedema 5Ref 5Kostis WJ, Shetty M, Chowdhury YS, Kostis JB (2018).ACE Inhibitor-Induced Angioedema: a Review.Angioedema incidence 0.1–0.7% of ACE inhibitor users; accounts for approximately one-third of ED angioedema visits; bradykinin mechanism; risk factors including African American race and female sex.

Angioedema is not the same as the cough, and it can occur in people who have never developed a cough. It can appear at any point during treatment, including years after starting the drug.

If you develop any swelling of the face, lips, tongue, or throat while on lisinopril, this is a medical emergency. See the safety section below.

When Should You Talk to a Clinician?

If you suspect your cough is from lisinopril:

• Contact your prescribing clinician at a convenient time — this does not need to be an emergency visit unless you have any of the warning signs below
• Tell them when the cough started relative to the medication and what it feels like (dry, tickling, persistent)
• Ask whether switching to an ARB makes sense for your specific situation
• Let them know about any associated symptoms — nasal congestion, heartburn, shortness of breath — so they can assess whether another cause is contributing

Do not quietly stop lisinopril without telling your prescriber. Blood pressure management matters, and the transition should be deliberate and monitored.